- Home
- DXLG vs ACRS Comparison
DXLG vs ACRS Comparison
Compare DXLG & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXLG
- ACRS
- Stock Information
- Founded
- DXLG 1976
- ACRS 2012
- Country
- DXLG United States
- ACRS United States
- Employees
- DXLG N/A
- ACRS N/A
- Industry
- DXLG Clothing/Shoe/Accessory Stores
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- DXLG Consumer Discretionary
- ACRS Health Care
- Exchange
- DXLG Nasdaq
- ACRS Nasdaq
- Market Cap
- DXLG 143.1M
- ACRS 132.0M
- IPO Year
- DXLG 1987
- ACRS 2015
- Fundamental
- Price
- DXLG $2.36
- ACRS $2.24
- Analyst Decision
- DXLG Buy
- ACRS Strong Buy
- Analyst Count
- DXLG 2
- ACRS 5
- Target Price
- DXLG $3.00
- ACRS $11.00
- AVG Volume (30 Days)
- DXLG 146.8K
- ACRS 656.6K
- Earning Date
- DXLG 03-20-2025
- ACRS 03-04-2025
- Dividend Yield
- DXLG N/A
- ACRS N/A
- EPS Growth
- DXLG N/A
- ACRS N/A
- EPS
- DXLG 0.15
- ACRS N/A
- Revenue
- DXLG $484,954,000.00
- ACRS $27,079,000.00
- Revenue This Year
- DXLG N/A
- ACRS N/A
- Revenue Next Year
- DXLG $1.65
- ACRS N/A
- P/E Ratio
- DXLG $15.75
- ACRS N/A
- Revenue Growth
- DXLG N/A
- ACRS 26.35
- 52 Week Low
- DXLG $2.15
- ACRS $0.95
- 52 Week High
- DXLG $4.16
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- DXLG 34.15
- ACRS 39.59
- Support Level
- DXLG $2.35
- ACRS $2.11
- Resistance Level
- DXLG $2.59
- ACRS $2.42
- Average True Range (ATR)
- DXLG 0.09
- ACRS 0.15
- MACD
- DXLG -0.04
- ACRS 0.00
- Stochastic Oscillator
- DXLG 2.38
- ACRS 26.53
About DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.